Curexa Pharmacy Expands Leadership with New Board Member Rachel Sherman, MD, MPH, FACP
EGG HARBOR TOWNSHIP, NJ – March 10, 2023 – Curexa Pharmacy (dba Curexa), a leading national
telemedicine pharmacy based in Egg Harbor Township, NJ, is proud to announce the appointment of
Rachel Sherman, MD, MPH, FACP, to its Board of Directors.
Dr. Sherman joins Curexa after nearly 30 years with the FDA, serving most recently as the Principal
Deputy Commissioner of Food and Drugs. Dr. Sherman, an internist with a subspecialty in infectious
diseases, is a fellow of the American College of Physicians. She has authored and co-authored
numerous seminal publications on topics ranging from clinical trials design and medical product
development, to the complexities of medical product regulation.
Dr. Sherman received her undergraduate degree from Washington University in St. Louis, earned her
medical degree from Mount Sinai School of Medicine, completed her internship and residency at
Montefiore Hospital and Medical Center, and holds a Masters of Public Health from Johns Hopkins
University. She completed her Fellowship in Infectious Diseases at Mount Sinai Hospital. Dr.
Sherman is passionate about clinical care and giving back to the future medical leaders of
tomorrow, having served as a clinical assistant professor at Georgetown University for eight years
and as an adjunct professor at Duke University School of Medicine for five years, while delivering
primary HIV care from the onset of the epidemic for more than two decades.
Dr. Sherman is honored to join the Board at Curexa, stating that, “I am delighted to join Curexa
and share Curexa’s core values for providing the highest quality of patient care and quality
standards. I look forward to collaborating with Mark Taylor and our partners to ensure Curexa
continues leading the compounding sector to attain Curexa’s level of excellence and commitment to
patient care, while providing access to affordable, personalized treatments to patients
throughout the country.”
Dr. Sherman joins Joel Wishkovsky, an entrepreneur, investor, and startup advisor specializing in
digital health and telemedicine as Curexa’s second independent board member. Curexa CEO, Mark
Taylor, Ph. MBA commented that, “We are so pleased that Rachel has joined us. With such a strong
and diverse Board of Directors, I am confident that Curexa will continue to serve our customers and
execute on our exciting strategic plans for the coming years.
John Pouschine, Curexa’s Chairman and co-founder of Pouschine Cook Capital Management, LLC, who
partnered with Curexa’s management team in November 2021, said that, “Recruiting a seasoned
independent board member with senior FDA experience demonstrates Curexa’s commitment to regulatory
compliance and the protection and safety of its patients. Rachel’s long tenure, numerous roles,
clinical experience, and award-winning career at the FDA are exactly what we were hoping to find.
With her support, we look forward to advancing the compound pharmacy industry’s quality and safety
standards while broadening access to medication through the adoption of telemedicine.”
Founded in 2003, Curexa has become an industry leading compounding pharmacy supporting DTC
telemedicine enterprises and others by offering fulfillment and pharmacy expertise to its client
partners across the United States. Curexa’s broad range of services include pre-launch support,
customized formulations, API integration, packaging/branding, and pharmacy regulatory compliance.
Curexa services a diverse range of partners including telemedicine companies, medical providers,
veterinarians, manufacturers and clinical research organizations. For additional information on
Curexa, please visit www.curexa.com.
About Pouschine Cook Capital Management, LLC
Pouschine Cook is a New York City-based private equity firm that invests in proven, private, lower
middle market companies, with a focus on healthcare services and B2B specialty products and
services. The Firm was founded in 1999 by John Pouschine and Everett Cook with a focus on companies
that are leaders in their respective sectors, have significant growth opportunities and are poised
to benefit from Pouschine Cook’s active involvement and enhancement expertise. Pouschine Cook
specializes in providing direct co-investment opportunities for institutional investors and family
offices alongside its own capital. For additional information on Pouschine
Cook, please visit www.pouschinecook.com.